Does ticagrelor reduce ischaemic events compared to clopidogrel in patients with acute coronary syndromes and diabetes?
Ticagrelor is superior to clopidogrel in reducing ischemic events in ACS patients regardless of their diabetes status or glycemic control, without increasing major bleeding risk.
ticagrelor, when compared with clopidogrel, reduced ischaemic events in ACS patients irrespective of diabetic status and glycaemic control, without an increase in major bleeding events.
James et al. (2010) studied this question.